ISSN 1662-4009 (online)

ESPE Yearbook of Paediatric Endocrinology (2022) 19 6.12 | DOI: 10.1530/ey.19.6.12


J Clin Endocrinol Metab. 2022 Jun 6:dgac349. PMID: 35666195, doi: 10.1210/clinem/dgac349.

Brief Summary: This paper reports the adult height of 161 transgender girls (registered male at birth) from the Amsterdam Cohort of Gender Dysphoria. It finds no difference in adult height between use of standard and high estrogen doses.

There is currently very little information on the effects of GnRH analogue and gender affirming hormone treatments on growth and adult height in transgender adolescents. In this large patient cohort, 73 transgender girls were close to adult height at the start of treatment. Of those still growing, GnRHa treatment slowed height velocity, and the start of estradiol treatment as expected caused a growth acceleration. The population of the Netherlands is amongst the tallest on the planet, and thus there are potentially more concerns around extreme tall stature in transgender women.

This study found no difference in the adult height achieved, in comparison with predicted or target heights. Furthermore, neither standard dose (2mg) nor high dose (6mg) estradiol treatment had a different outcome in this regard. Those patients who were historically given high dose ethinylestradiol had only a small reduction (3cm) in adult height. This particular treatment is no longer recommended in tall girls due to reduced fertility and potential longer term cancer risks and the authors state that transgender girls might be at similar risk.

Article tools

My recent searches

No recent searches.